{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:39:31Z","timestamp":1773797971374,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["JPMH23FC1035"],"award-info":[{"award-number":["JPMH23FC1035"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["JP25K02583"],"award-info":[{"award-number":["JP25K02583"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["JP22K07528"],"award-info":[{"award-number":["JP22K07528"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-026-13618-2","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:26:35Z","timestamp":1768836395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study"],"prefix":"10.1007","volume":"273","author":[{"given":"Shizuka","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-1307","authenticated-orcid":false,"given":"Makoto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"4","key":"13618_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","volume":"75","author":"GG Cornwell","year":"1983","unstructured":"Cornwell GG, Murdoch WL, Kyle RA et al (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618\u2013623. https:\/\/doi.org\/10.1016\/0002-9343(83)90443-6","journal-title":"Am J Med"},{"issue":"12","key":"13618_CR2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","volume":"24","author":"M Ueda","year":"2011","unstructured":"Ueda M, Horibata Y, Shono M et al (2011) Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 24(12):1533\u20131544. https:\/\/doi.org\/10.1038\/modpathol.2011.117","journal-title":"Mod Pathol"},{"issue":"38","key":"13618_CR3","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"issue":"11","key":"13618_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","volume":"42","author":"Y Sekijima","year":"2011","unstructured":"Sekijima Y, Uchiyama S, Tojo K et al (2011) High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 42(11):1785\u20131791. https:\/\/doi.org\/10.1016\/j.humpath.2011.03.004","journal-title":"Hum Pathol"},{"issue":"9","key":"13618_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","volume":"42","author":"T Sueyoshi","year":"2011","unstructured":"Sueyoshi T, Ueda M, Jono H et al (2011) Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol 42(9):1259\u20131264. https:\/\/doi.org\/10.1016\/j.humpath.2010.11.017","journal-title":"Hum Pathol"},{"issue":"1","key":"13618_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","volume":"23","author":"M Nakagawa","year":"2016","unstructured":"Nakagawa M, Sekijima Y, Yazaki M et al (2016) Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid 23(1):58\u201363. https:\/\/doi.org\/10.3109\/13506129.2015.1135792","journal-title":"Amyloid"},{"issue":"2","key":"13618_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/modpathol.2014.102","volume":"28","author":"A Yanagisawa","year":"2015","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T et al (2015) Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol 28(2):201\u2013207. https:\/\/doi.org\/10.1038\/modpathol.2014.102","journal-title":"Mod Pathol"},{"issue":"4","key":"13618_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.rec.2024.07.005","volume":"78","author":"P Garc\u00eda-Pav\u00eda","year":"2025","unstructured":"Garc\u00eda-Pav\u00eda P, Garc\u00eda-Pinilla JM, Lozano-Bahamonde A et al (2025) Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol (Engl Ed) 78(4):301\u2013310. https:\/\/doi.org\/10.1016\/j.rec.2024.07.005","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"11","key":"13618_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"issue":"2","key":"13618_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390(2):132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"issue":"1","key":"13618_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD et al (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"},{"issue":"1","key":"13618_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS et al (2022) Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 15(1):e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193","journal-title":"Circ Heart Fail"},{"issue":"10","key":"13618_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014\u20131020. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"13618_CR14","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ehf2.13851","volume":"9","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Jakstaite AM, Oubari S et al (2022) Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis. ESC Heart Fail 9(3):1740\u20131748. https:\/\/doi.org\/10.1002\/ehf2.13851","journal-title":"ESC Heart Fail"},{"issue":"9","key":"13618_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M et al (2020) Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 6(9):1118\u20131127. https:\/\/doi.org\/10.1016\/j.jacep.2020.04.019","journal-title":"JACC Clin Electrophysiol"},{"issue":"13","key":"13618_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","volume":"73","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro A, Gonzalez-Lopez E, Corovic A et al (2019) High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol 73(13):1733\u20131734. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.035","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"13618_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ejhf.2566","volume":"24","author":"S Vilches","year":"2022","unstructured":"Vilches S, Fontana M, Gonzalez-Lopez E et al (2022) Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 24(8):1387\u20131396. https:\/\/doi.org\/10.1002\/ejhf.2566","journal-title":"Eur J Heart Fail"},{"key":"13618_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2022.04.045","volume":"358","author":"Z Dale","year":"2022","unstructured":"Dale Z, Chandrashekar P, Al-Rashdan L et al (2022) Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis. Int J Cardiol 358:65\u201371. https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.045","journal-title":"Int J Cardiol"},{"issue":"11","key":"13618_CR19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1212\/01.wnl.0000276951.39112.2b","volume":"69","author":"AY Zubkov","year":"2007","unstructured":"Zubkov AY, Rabinstein AA, Dispenzieri A et al (2007) Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 69(11):1136\u20131141. https:\/\/doi.org\/10.1212\/01.wnl.0000276951.39112.2b","journal-title":"Neurology"},{"issue":"5","key":"13618_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.20617","volume":"58","author":"H Ay","year":"2005","unstructured":"Ay H, Furie KL, Singhal A et al (2005) An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 58(5):688\u2013697. https:\/\/doi.org\/10.1002\/ana.20617","journal-title":"Ann Neurol"},{"issue":"24","key":"13618_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"issue":"9","key":"13618_CR22","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y et al (2020) JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 84(9):1610\u20131671. https:\/\/doi.org\/10.1253\/circj.CJ-20-0110","journal-title":"Circ J"},{"issue":"10","key":"13618_CR23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller HI, Singh A, Alexander KM et al (2017) Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 318(10):962\u2013963. https:\/\/doi.org\/10.1001\/jama.2017.9236","journal-title":"JAMA"},{"issue":"9216","key":"13618_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s0140-6736(00)02237-6","volume":"355","author":"PA Barber","year":"2000","unstructured":"Barber PA, Demchuk AM, Zhang J et al (2000) Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 355(9216):1670\u20131674. https:\/\/doi.org\/10.1016\/s0140-6736(00)02237-6","journal-title":"Lancet"},{"key":"13618_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2021.10.007","volume":"79","author":"S Takashio","year":"2022","unstructured":"Takashio S, Yamada T, Nishi M et al (2022) Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. J Cardiol 79:50\u201357. https:\/\/doi.org\/10.1016\/j.jjcc.2021.10.007","journal-title":"J Cardiol"},{"issue":"1","key":"13618_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB (2020) Epidemiology of atrial fibrillation in the 21st century: novel methods and novel insights. Circ Res 127(1):4\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316340","journal-title":"Circ Res"},{"key":"13618_CR27","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/ehf2.12884","volume":"7","author":"T Yamada","year":"2020","unstructured":"Yamada T, Takashio S, Arima Y et al (2020) Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail 7:2829\u20132837. https:\/\/doi.org\/10.1002\/ehf2.12884","journal-title":"ESC Heart Fail"},{"issue":"1","key":"13618_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","volume":"28","author":"F Cappelli","year":"2021","unstructured":"Cappelli F, Tini G, Russo D et al (2021) Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid 28(1):12\u201318. https:\/\/doi.org\/10.1080\/13506129.2020.1798922","journal-title":"Amyloid"},{"issue":"12","key":"13618_CR29","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","volume":"5","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Elshazly MB, Vakamudi S et al (2019) No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 5(12):1473\u20131474. https:\/\/doi.org\/10.1016\/j.jacep.2019.10.013","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"13618_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","volume":"15","author":"F Bandera","year":"2022","unstructured":"Bandera F, Martone R, Chacko L et al (2022) Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging 15(1):17\u201329. https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.022","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13618-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13618-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13618-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:05:11Z","timestamp":1773785111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13618-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13618"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13618-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Makoto Nakajima received lecture fees and honoraria from Bayer, Pfizer and Daiichi Sankyo. Yohei Misumi received research grants from Alnylam and Pfizer. Yasuhiro Izumiya received lecture fees from Pfizer Japan Inc. Kenichi Tsujita received research grants and lecture fees from Alexion Pharma GK and Pfizer Japan, Inc. Kazumi Kimura received lecture fees and honoraria from Daiichi Sankyo. Yukio Ando received research grants and lecture fees from Alnylam and Pfizer. Mitsuharu Ueda received research grants and lecture fees from Alnylam and Pfizer. All reported disclosures are outside the scope of this study. Other authors reported no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Kumamoto University Hospital (Approval No. 3187). The requirement for written informed consent was waived owing to the retrospective nature of the study. Instead, information about the study was publicly disclosed and an opt-out method was used to provide patients with the opportunity to refuse the use of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"86"}}